$495 Million is the total value of Opaleye Management Inc.'s 48 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 158.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TARA | New | PROTARA THERAPEUTICS INC | $64,752,000 | – | 2,208,472 | +100.0% | 13.08% | – |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $49,848,000 | +96.6% | 5,984,200 | +16.8% | 10.07% | +49.8% |
| HROW | New | HARROW HEALTH INC | $14,119,000 | – | 2,710,000 | +100.0% | 2.85% | – |
| MYOV | Buy | MYOVANT SCIENCES LTD | $14,073,000 | +184.1% | 682,500 | +4.0% | 2.84% | +116.5% |
| MGNX | Buy | MACROGENICS INC | $13,988,000 | +469.1% | 501,000 | +18.6% | 2.82% | +333.9% |
| CLDX | New | CELLDEX THERAPEUTICS INC | $13,923,000 | – | 1,071,000 | +100.0% | 2.81% | – |
| FBIO | New | FORTRESS BIOTECH INC | $10,264,000 | – | 3,830,000 | +100.0% | 2.07% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $8,778,000 | – | 344,500 | +100.0% | 1.77% | – |
| CERC | Buy | CERECOR INC | $8,768,000 | +60.5% | 3,372,500 | +53.1% | 1.77% | +22.3% |
| QURE | Buy | VAXCYTE | $8,547,000 | -14.2% | 270,400 | +28.8% | 1.73% | -34.6% |
| BHVN | New | BIOHAVEN PHARMACEUTICAL HLDG | $8,360,000 | – | 114,350 | +100.0% | 1.69% | – |
| XOMA | Buy | XOMA CORP DEL | $8,208,000 | +4.2% | 415,380 | +7.3% | 1.66% | -20.6% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $7,625,000 | +40.7% | 435,200 | +18.0% | 1.54% | +7.2% |
| CYTK | New | CYTOKINETICS INC | $7,143,000 | – | 303,050 | +100.0% | 1.44% | – |
| TCDA | Buy | TRICIDA INC | $6,548,000 | +53.4% | 238,300 | +22.8% | 1.32% | +16.9% |
| CMRX | New | CHIMERIX INC | $6,526,000 | – | 2,105,000 | +100.0% | 1.32% | – |
| MEIP | New | MEI PHARMA INC | $6,426,000 | – | 1,556,000 | +100.0% | 1.30% | – |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $5,584,000 | +224.5% | 461,500 | +105.1% | 1.13% | +147.4% |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $5,336,000 | +32.0% | 1,155,000 | +10.0% | 1.08% | +0.7% |
| BTAI | New | BIOXCEL THERAPEUTICS INC | $4,983,000 | – | 94,000 | +100.0% | 1.01% | – |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $3,582,000 | +59.4% | 970,664 | +7.1% | 0.72% | +21.5% |
| LQDA | New | LIQUIDIA TECHOLOGIES INC | $3,368,000 | – | 400,000 | +100.0% | 0.68% | – |
| ARDX | New | ARDELYX INC | $3,263,000 | – | 471,600 | +100.0% | 0.66% | – |
| TELA | Buy | TELA BIO INC | $3,240,000 | +411.8% | 250,000 | +208.6% | 0.65% | +289.3% |
| CRDF | New | CARDIFF ONCOLOGY INC | $2,956,000 | – | 590,000 | +100.0% | 0.60% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $2,458,000 | – | 960,000 | +100.0% | 0.50% | – |
| FENC | New | FENNEC PHARMACEUTICALS INC | $1,428,000 | – | 171,000 | +100.0% | 0.29% | – |
| EPIX | New | ESSA PHARMA INC | $1,085,000 | – | 175,000 | +100.0% | 0.22% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCsponsored ads | $962,000 | – | 60,000 | +100.0% | 0.19% | – |
| ASRT | New | ASSERTIO HOLDINGS INC | $754,000 | – | 880,000 | +100.0% | 0.15% | – |
| BLRX | New | BIOLINERX LTDsponsored ads | $29,000 | – | 16,667 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.